SEED 2 SEQUOIA THERAPY LIMITED

Company Registration Number:
14902258 (England and Wales)

Unaudited micro entity accounts for the year ended 31 May 2024

Period of accounts

Start date: 30 May 2023

End date: 31 May 2024

SEED 2 SEQUOIA THERAPY LIMITED

Contents of the Financial Statements

for the Period Ended 31 May 2024

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Footnotes to the Balance Sheet - 8

SEED 2 SEQUOIA THERAPY LIMITED

Company Information

for the Period Ended 31 May 2024




Director: Cindy Banjoko
Registered office: Flat 37 Webb House
Hemans Street
London
England
SW8 4SU
Company Registration Number: 14902258 (England and Wales)

SEED 2 SEQUOIA THERAPY LIMITED

Directors' Report Period Ended 31 May 2024

The directors present their report with the financial statements of the company for the period ended 31 May 2024

Principal Activities

Agents involved in the sale of a variety of goods

Directors

The director(s) shown below were appointed to the company during the period
Cindy Banjoko
30 May 2023

This report was approved by the board of directors on 20 August 2024
And Signed On Behalf Of The Board By:

Name: Cindy Banjoko
Status: Director

SEED 2 SEQUOIA THERAPY LIMITED

Profit and Loss Account

for the Period Ended 31 May 2024


2024
£
Turnover 2,522
Cost of Materials ( 1,709 )
Profit or (Loss) for Period 813

SEED 2 SEQUOIA THERAPY LIMITED

Balance sheet

As at 31 May 2024


2024
£
Fixed Assets: 100
Total assets less current liabilities: 100
Total net assets (liabilities): 100
Capital and reserves: 100

SEED 2 SEQUOIA THERAPY LIMITED

Balance sheet continued

For the year ending 31 May 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 20 August 2024
And Signed On Behalf Of The Board By:

Name: Cindy Banjoko
Status: Director

The notes form part of these financial statements

SEED 2 SEQUOIA THERAPY LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 May 2024

  • 1. Employee Information

    Average number of employees: 1

SEED 2 SEQUOIA THERAPY LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 May 2024

  • 2. Off balance sheet disclosure

    No